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Abstract 
Psoriasis (PsO) has been associated with obesity, and its severity increases in obese subjects. 
The link between psoriatic condition and obesity is based on shared pathophysiological path-
ways where local and systemic inflammation promote each other; PsO is an inflammatory, im-
mune-mediated disease, and the adipose tissue is the source of proinflammatory adipokines. 
Moreover, psoriatic arthritis (PsA) is an important comorbidity of PsO that reduces quality of 
life and makes difficult the patient’s management. Treatment of obese subjects with moderate 
to severe PsO, even more if PsA is present, is challenging because of reduced efficacy of several 
systemic drugs and increased risk of adverse events. Secukinumab, a monoclonal antibody that 
selectively binds to and neutralizes interleukin 17A, shows efficacy on PsO in all body weight 
groups, even in the highest, whose response has a slight downward trend. Clinical features of 
two obese subjects, affected by PsO and PsA, successfully treated with secukinumab, are de-
scribed. © 2019 The Author(s) 
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Psoriasis Comorbidities 
Psoriasis is a complex, chronic, immune-mediated inflammatory skin disorder. Psoriatic 
arthritis and metabolic syndrome are common comorbidities in patients with psoriasis; their 
frequency presents a wide variation depending on population groups observed. In a recent 
publication by Souza et al. [1], the authors stated that among comorbidities associated with 
psoriasis and strictly related to the patient’s quality of life, the prevalence of metabolic syn-
drome and psoriatic arthritis was 50 and 41.8%, respectively. Dyslipidemia was the most 
prevalent secondary comorbidity, followed by hypertension, obesity, and type 2 diabetes 
mellitus. A diminished health-related quality of life is observed among psoriatic patients with 
these comorbidities, highlighting the importance of diagnosis and successful treatment be-
yond the skin lesion resolution [1]. 
The Association between Psoriasis and Obesity 
Epidemiological studies suggested that patients with psoriasis, compared with the gen-
eral population, have higher prevalence and incidence of obesity [2]. A meta-analysis of 16 
observational studies found that the pooled odds ratio (OR) for obesity among patients with 
psoriasis was 1.66 (95% confidence interval [CI] 1.46–1.89) compared with those without 
psoriasis [2]. From the studies that reported psoriasis severity, the pooled OR for obesity 
among patients with mild psoriasis was 1.46 (95% CI 1.17–1.82) and the pooled OR for pa-
tients with severe psoriasis was 2.23 (95% CI 1.63–3.05). An incidence study found that pso-
riasis patients have a hazard ratio of 1.18 (95% CI 1.14–1.23) for new-onset obesity [2]. Pso-
riasis was found to be associated with abdominal obesity, which is a proxy measure of visceral 
adipose tissue, and is a well-recognized risk factor for type 2 diabetes mellitus, hypertension, 
coronary artery disease, and decreased life expectancy [3]. The prospective Nurses’ Health 
Study II observed that psoriasis was more common in subjects with an increased waist cir-
cumference, a surrogate marker for abdominal visceral fat [4]. 
Pathophysiological Basis Linking Psoriasis and Obesity 
Although the mechanism underlying the epidemiological association between psoriasis 
and obesity is not completely understood, inflammation is considered the pathophysiological 
basis between the two conditions [2]. Obesity is a further source of inflammation in psoriatic 
subjects. White adipose tissue, which is the primary component of visceral fat, is composed of 
both adipocytes and other immunologically active cells such as macrophages [5]. Adipocytes 
secrete adipokines with pro-inflammatory properties, such as leptin, visfatin, and resistin [5]; 
their expression was found to exacerbate psoriasis [2]. Besides that, a common genetic link 
between psoriasis and obesity was demonstrated in a cross-sectional, population-based twin 
study in 33,588 Danish subjects (OR, 1.81; 95% CI, 1.28–2.55; p = 0.001 in subjects with a BMI 
>35) [6]. On the contrary, body weight reduction has been shown to attenuate the severity of 
plaque psoriasis. A randomized controlled study investigated the impact of hypocaloric die-
tary intervention and physical activity over 20 weeks in 303 overweight/obese patients with 
moderate to severe plaque psoriasis. Psoriasis area and severity index score was reduced by 
48% in the interventional arm (where the weight loss target of ≥5% was achieved in 29.8% of 
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subjects), compared to only 25.5% in the information only arm (weight loss target achieved 
in 14.5% of subjects) (p = 0.02) [7]. 
Systemic Antipsoriatic Treatments in Obese Patients 
The use of systemic antipsoriatic treatments was observed to have poorer benefit and a 
higher incidence of adverse events in obese subjects compared to patients with normal body 
weight. With regard to this, methotrexate carries a higher risk of fatty liver and hepatic fibrosis 
in obese patients and therefore should be avoided [8]. In addition, obese patients require 
higher doses of acitretin and cyclosporine, which leads to increased risk of side effects [9]. 
Furthermore, several studies have shown that therapeutic response to anti-tumor necrosis 
factor (TNF)-α agent is better in patients with normal BMI, versus those with higher BMI, and 
that reduction in body weight leads to a better response [9]. Indeed, one of the variables most 
related to increased clearance of the drug is weight. Individuals weighing more than 100 kg 
clear the drug 55% faster and have 35% greater volume of distribution, which both lead to 
lower trough levels at the time of re-dosing [10]. Obesity-related drug excretion may be com-
pounded by the presence of diabetes mellitus, and individuals with both a weight greater than 
100 kg and diabetes were found to have very high clearance rates and approximately 50% 
lower trough levels during therapy. This issue has been demonstrated for ustekinumab, a 
monoclonal antibody targeting interleukin (IL)-12 and IL-23, in the PHOENIX trials, at the rec-
ommended doses of 45/90 mg, where the nonresponders were found to have the highest rates 
of apparent drug clearance that may be associated with ustekinumab efficacy [10]. 
Secukinumab and Obesity 
Secukinumab is a monoclonal antibody that selectively binds to and neutralizes IL-17A. It 
has shown efficacy in the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis 
[11]. In subjects with psoriasis, expression of IL-17 mRNA is higher in lesional compared with 
nonlesional skin [12]. Moreover, IL-17A levels were found to be significantly correlated to dis-
ease severity [13, 14]. Blockade of IL-17 reduced keratinocyte hyperproliferation, T-cell infil-
tration into the dermis, and mRNA expression of disease-propagating genes [15]. Thus, there 
is a considerable amount of data supporting the central role of IL-17 in the pathogenesis of 
psoriasis and the value of IL-17-targeted biologic therapy. Finally, some data seem to suggest 
that adipocytokines could also interfere with the IL-17 pathway [16–18]. 
Secukinumab is a highly efficacious drug irrespective of body weight. In a pooled analysis 
of phase III trials, ERASURE and FIXTURE, responses were analyzed by body weight quartiles 
(42–69.9, 70–82, 82.1–97, and 97.1–219.1 kg): pooled PASI 75, PASI 90, and PASI 100 re-
sponse rates were high across weight quartiles and were maintained at week 52. Even though 
responses remained clinically meaningful in all weight groups, there was a trend for a lower 
response by increasing body weight. Moreover, secukinumab 300 mg dose demonstrated con-
sistently greater benefit than the 150 mg dose across weight quartiles [19]. Also, data from 
the CLEAR phase III study showed that secukinumab 300 mg had a clinically and statistically 
significantly higher efficacy (PASI 90 at week 16) than ustekinumab 90 mg in patients with a 
body weight over 100 kg. This result was fully sustained at week 52 [20]. Unlike TNF-α inhib-
itors, IL-17 inhibitors have not been observed to cause weight gain in clinical trials [9]. 
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Case Reports 
Clinical experiences with two obese subjects, with very high BMI, affected by moderate to 
severe psoriasis and by psoriatic arthritis, successfully treated with secukinumab are de-
scribed. These experiences represent typical examples of difficult patients that need to be 
managed in agreement with the previous literature. 
Patient 1 
A male patient with a family history of psoriasis had been diagnosed with plaque psoriasis 
when he was 27 years old and with psoriatic arthritis when he was 29. He had received re-
peated cycles of acitretin without benefit and had been treated for 3 years with sulfasalazine 
and an oral corticosteroid. Methotrexate had been then administered without improvement 
of skin lesions. At first presentation, in December 2016, the patient was 36 years old, had BMI 
45.38, and plaque psoriasis with a PASI 24 (Fig. 1a, b). The patient reported articular pain and 
itching. Methotrexate had been discontinued 1 month before. Secukinumab 300 mg subcuta-
neous was administered at weeks 0, 1, 2, 3, 4, and subsequently every 4 weeks. 
After 1 month of treatment, an unsatisfactory improvement was observed, with PASI 20 
(Fig. 1c). After 4 months of therapy, PASI was 7, the trunk was cleared and limb lesions were 
not infiltrated (Fig. 1d, e). Itching and articular pain were not reported. 
Currently, after 2 years of therapy, the PASI index is 3 and we observe only few nummular 
erythematous lesions with little infiltration at the bilateral pre-tibia regions. The patient also 
denies the appearance of joint pain. 
Patient 2 
A 58-year-old female presented with itching disseminated psoriatic lesions, with a PASI 
14 (Fig. 2a). She was obese, with BMI 49.59. The woman had been diagnosed with psoriatic 
arthritis 3 years before because of joint pain and had received nonsteroidal anti-inflammatory 
drugs and later methotrexate 15 mg/week for 1 year. This therapy had not been effective. 
Secukinumab 300 mg subcutaneous was administered at weeks 0, 1, 2, 3, 4, and subsequently 
every 4 weeks. Skin lesion improvement was observed 3 months later, but psoriasis persisted 
on the back, with a PASI 6 (Fig. 2b). Psoriasis was completely cleared (PASI 0) after 6 months 
of treatment (Fig. 2c). 
Currently, the patient has almost reached 2 years of treatment and her PASI index has 
always remained at 0. The patient reported that joint pain was absent. 
Discussion and Conclusion 
Obese subjects have a high prevalence of psoriasis and are less efficiently treated with 
systemic agents, due to both reduced efficacy and increased risk of adverse events. Psoriatic 
arthritis is a common comorbidity of psoriasis. Secukinumab is effective on both skin psoriasis 
and psoriatic arthritis, and efficacy in psoriasis was demonstrated by clinical trials in all body 
weight groups. In this article, two exemplary complex cases are reported: two obese patients, 
with comorbid psoriatic arthritis, were successfully treated with secukinumab, for both ar-
thritis and skin psoriasis. 
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Key Message 
An association between psoriasis and obesity was found. Secukinumab is effective in 
obese patients with psoriasis and psoriatic arthritis. 
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Fig. 1. Patient No. 1, at presentation (a, b), after 1 month (c), and 4 months (d, e) of secukinumab treatment. 
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Fig. 2. Patient No. 2, at presentation (a), after 3 months (b), and 6 months (c) of secukinumab treatment. 
 
